Increase CRC screening rates

One goal—improved CRC screening

We are here to collaborate with you on scaling colorectal cancer (CRC) solutions, the benefits of timely CRC screening, and the Cologuard® test.
Physician reviewing CRC screening rates on a large lightboard with six monitors.
Scalable CRC screening solutions
See how the Cologuard test can help close the CRC screening gap.
Physician introducing informed decision making and discussing colorectal cancer screening options with a patient who is sitting on an exam table.
Support a positive patient experience through timely CRC screening
Learn more about the benefits of prioritizing CRC screening.
A healthcare provider reviewing a document with 4 health system leaders around a table.
Strategies to boost CRC screening rates and adherence
See the support for how the Cologuard test can boost CRC screening rates and adherence.1,2*  
Four healthcare providers having a discussion in a healthcare setting.
Best-in-class, noninvasive detection
Learn about how, among USPSTF-recommended screening methods, the Cologuard® test delivers higher sensitivity than other noninvasive options, like the fecal immunochemical test (FIT).3,4

Footnote and references

  1. Based on patients who completed screening within 90 days of receiving Cologuard test kits for their second CRC screening from October 2020 to December 2021.3

  1. Prince M, Lester L, Chiniwala R, Berger B. Multitarget stool DNA tests increases colorectal cancer screening among previously nonadherence Medicare patients. World J Gastroenterol. 2017;23(3):464-471.
  2. Data on file for 2022 rescreen. Cologuard Monitoring and Response. 2022. Exact Sciences Corporation. Madison, WI.
  3. Cologuard® Clinician Brochure. Madison, WI: Exact Sciences Corporation.
  4. Davidson KW, Barry MJ, Mangione CM, et al. Screening for colorectal cancer US Preventive Services Task Force recommendation statement. JAMA. 2021;325(19):1965-1977.

Important Information about the Cologuard products


Indications for Use

The Cologuard® and Cologuard Plus™ tests are intended for the qualitative detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. A positive result may indicate the presence of colorectal cancer (CRC) or advanced adenoma (AA)/advanced precancerous lesions (APL) and should be followed by a colonoscopy. The Cologuard test and Cologuard Plus test are indicated to screen adults of either sex, 45 years or older, who are at average risk for CRC. These tests are not a replacement for diagnostic colonoscopy or surveillance colonoscopy in high-risk individuals.

Contraindications

The Cologuard products are not for high-risk individuals, including patients who have the following:

  • a personal history of colorectal cancer and adenomas
  • a positive result from another colorectal cancer screening method within a test recommended timeframe
  • have been diagnosed with a condition associated with high risk for colorectal cancer such as IBD, chronic ulcerative colitis, Crohn’s disease
  • have a family history of colorectal cancer, or certain hereditary syndromes

Warnings and Precautions

All positive results should be referred to colonoscopy.

The Cologuard products may produce false positive and false negative results. A false positive result occurs when a result is positive, even though a colonoscopy will not find CRC or APL. A false negative result occurs when a result is negative, even when a colonoscopy identifies APL or CRC.

A negative result does not guarantee the absence of colorectal cancer or advanced adenoma. Following a negative result, patients should continue participating in a screening program at an interval and with a method appropriate for the individual patient. Performance when used for repeat testing has not been established.

Refer to the Cologuard test Clinician Brochure or the Cologuard Plus test Clinician Brochure for additional information about the benefits and risks of using each version of the Cologuard product for CRC screening.

Rx only.